NCT02327546
Source recordAI-normalized
An Open-Label, Randomized, Single-Dose Study to Evaluate the Effects of 325 mg Ferrous Sulfate Tablet (65 mg Iron) on the Pharmacokinetics of 450 mg Dose of AKB-6548 in Healthy Male Volunteers.
This clinical trial, sponsored by Akebia Therapeutics, evaluated the pharmacokinetics of AKB-6548 in healthy male volunteers, specifically assessing the impact of ferrous sulfate on its bioavailability. The study involved a randomized, crossover design with 10 participants.
AI analysis
Indication: Healthy Volunteers
Modality: small molecule
Target: AKB-6548
Sponsor: Akebia Therapeutics
Source URL: ClinicalTrials.gov
Source updated: Nov 14, 2018
Ingested: Jun 03, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: AKB-6548
View original source fields
Condition raw: Healthy Volunteers
Condition normalized: Healthy Volunteers
Modality raw: Healthy Volunteers
Modality normalized: small molecule
Target raw: AKB-6548
Target normalized: AKB-6548